Molecular advances in prostate cancer

Current Opinion in Oncology

Volumn 9, Issue 1, 1997, Pages 101-107

  Dong, Jin Tang ^a   Isaacs, William B ^a   Isaacs, John T ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGENESIS; CHROMOSOME 8Q; CHROMOSOME LOSS; ENVIRONMENTAL EXPOSURE; GENE LOCUS; GENE SEGREGATION; HUMAN; MOLECULAR GENETICS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; STEM CELL; TUMOR SUPPRESSOR GENE;

EID: 0030953945     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199701000-00016     Document Type: Review

References (99)

1. Carter HB, Piantadosi S, Isaacs JT: Clinical evidence for and implications of the multistep development of prostate cancer. J Urol 1990, 143:742-746.
2. Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allred DC: P53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 1993, 53:3369-3373.
3. Carter BS, Carter HB, Isaacs JT: Epidemiologic evidence regarding predisposing factors to prostate cancer. Prostate 1990, 16:187-197.
4. Dhom G: Epidemiologic aspects of latent and clinically manifest carcinoma of the prostate. J Cancer Res Clin Oncol 1983, 106:210-218.
5. Yatani R, Chigusa I, Akazaki K, Stemmermann GN, Welsh RA, Correa P: Geographic pathology of latent prostatic carcinoma. Int J Cancer 1982, 29:611-616.
6. Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC: Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci U S A 1992, 89:3367-3371.
7. Carter BS, Bova GS, Beaty TH, Steinberg GD, Childs B, Isaacs WB, Walsh PC: Hereditary prostate cancer: epidemiologic and clinical features. J Urol 1993, 150:797-802.
8. Smith RS, Freije D, Carpten JD, Gronberg H, Xu J, Isaacs SD, Brownstein MJ, Bova GS, Guo H, Bujnovszky P, et al.: Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 1996, 274:1371-1374 This paper provides more evidence for hereditary prostate cancer.
9. Kallioniemi A, Kallioniemi O-P, Sudar D, Rutovitz D, Gray JW, Waldman F, Pinkel D: Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 1992, 258:818-821.
10. Hermsen M, Meijer GA, Baak JPA, Joenje H, Walboomers JJM: Comparative genomic hybridization: a new tool In cancer pathology. Hum Pathol 1996, 27:342-349. A review article on the recently developed technique of comparative genomic hybridization.
11. Berthon P, Dimitrov T, Stower M, Cussenot O, Maitland NJ: A microdissection approach to detect molecular markers during progression of prostate cancer. Br J Cancer 1995, 72:946-951.
12. Zhuang Z, Bertheau P, Emmert-Buck MR, Liotta LA, Gnarra J, Linehan WM, Lubensky IA: A microdissection technique for archival DNA analysis of specific cell populations in lesions <1 mm in size. Am J Pathol 1995, 146:620-625. In this paper the microdissection method is introduced.
13. Qian J, Bostwick DG, Takahashi S, Borell TJ, Herath JF, Lieber MM, Jenkins RB: Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Cancer Res 1995, 55:5408-5414.
14. Emmert-Buck MR, Vocke CD, Pozzatti RO, Duray PH, Jennings SB, Florence CD, Zhuang Z, Bostwick DG, Liotta LA, Linehan WM: Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. Cancer Res 1995, 55:2959-2962. PIN arises multifocally within the prostate gland, a subset of these lesions become carcinoma.
15. Cher ML, MacGrogan D, Bookstein R, Brown JA, Jenkins RB, Jensen RH: Comparative genomic hybridization, allelic imbalance, and fluorescence in situ hybridization on chromosome 8 in prostate cancer. Genes Chromosomes Cancer 1994, 11:153-162.
16. Cher ML, Bova GS, Moore DH, Small EJ, Carroll PR, Pin SS, Epstein JI, Isaacs WB, Jensen RH: Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res 1996, 56:3091-3102.
17. Joos S, Bergerheim USR, Pan Y, Matsuyama H, Bentz M, Dumanoir S, Lichter P: Mapping of chromosomal gains and losses in prostate cancer by comparative genomic hybridization. Genes Chromosomes Cancer 1995, 14:267-276.
18. Visakorpi T, Kallioniemi AH, Syvanen AC, Hyytinen ER, Karhu R, Tammela T, Isola JJ, Kallioniemi OP: Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res 1995, 55:342-347.
19. Takahashi S, Alcaraz A, Brown JA, Borell TJ, Herath JF, Bergstralh EJ, Lieber MM, Jenkins RB: Aneusomies of chromosomes 8 and Y detected by fluorescence in situ hybridization are prognostic markers for pathological stage C (pT3N0M0) prostate carcinoma. Clin Cancer Res 1996, 2:137-145.
20. Wang R-Y, Troncoso P, Palmer JL, El-Naggar AK, Liang JC: Trisomy 7 by dual-color fluorescence in situ hybridization: a potential biological marker for prostate cancer progression. Clin Cancer Res 1996, 2:1553-1558. Trisomy 7 and the possibility of it being a marker for advanced prostate cancer is discussed in this paper.
21. Qian J, Jenkins RB, Bostwick DG: Chromosomal anomalies in atypical adenomatous hyperplasia and carcinoma of the prostate using fluorescence in situ hybridization. Urology 1995, 46:837-842
22. Takahashi S, Qian J, Brown JA, Alcaraz A, Bostwick DG, Lieber MM, Jenkins RB: Potential markers of prostate cancer aggressiveness detected by fluorescence in situ hybridization in needle biopsies. Cancer Res 1994, 54:3574-3579.
23. Macoska JA, Trybus TM, Sakr WA, Wolf MC, Benson PD, Powell IJ, Pontes JE: Fluorescence in situ hybridization analysis of Bp allelic loss and chromosome 8 instability in human prostate cancer. Cancer Res 1994, 54:3824-3830.
24. Macoska JA, Trybus TM, Benson PD, Sakr WA, Grignon DJ, Wojno KD, Pietruk T, Powell IJ: Evidence for three tumor suppressor gene loci on chromosome 8p in human prostate cancer. Cancer Res 1995, 55:5390-5395. Multiple loci on chromosome 8p being involved in prostatic carcinogenesis is discussed here.
25. MacGrogan D, Levy A, Bostwick D, Wagner M, Wells D, Bookstein R: Loss of chromosome arm 8p loci in prostate cancer: mapping by quantitative allelic imbalance. Genes Chromosom Cancer 1994, 10:151-159.
26. Sakr WA, Macoska JA, Benson P, Grignon DJ, Wolman SR, Pontes JE, Crissman JD: Allelic loss in locally metastatic, multisampled prostate cancer. Cancer Res 1994, 54:3273-3277.
27. Trapman J, Sleddens HF, van der Weiden MM, Dinjens WN, Konig JJ, Schroder FH, Faber PW, Bosman FT: Loss of heterozygosity of chromosome 8 microsatellite loci implicates a candidate tumor suppressor gene between the loci D8S87 and D8S133 in human prostate cancer. Cancer Res 1994, 54:6061-6064.
28. Bova GS, Carter BS, Bussemakers MJ, Emi M, Fujiwara Y, Kyprianou N, Jacobs SC, Robinson JC, Epstein JI, Walsh PC, Isaacs WB: Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res 1993, 53:3869-3873.
29. Macgrogan D, Levy A, Bova GS, Isaacs WB, Bookstein R: Structure and methylation-associated silencing of a gene within a homozygously deleted region of human chromosome band 8p22. Genomics 1996, 35:55-65.
30. Cunningham JM, Shan A, Wick MJ, McDonnell SK, Schaid DJ, Tester DJ, Qian J, Takahashi S, Jenkins RB, Bostwick DG, Thibodeau SN: Allelic imbalance and microsatellite instability in prostatic adenocarcinoma. Cancer Res 1996, 56:4475-4482. In this paper microsatellite markers from every chromosome were used to study allelic loss and microsatellite instability in prostate cancer.
31. Vocke CD, Pozzatti RO, Bostwick DG, Florence CD, Jennings SB, Strup SE, Duray PH, Liotta LA, Emmert-Buck MR. Linehan WM: Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-21. Cancer Res 1996, 56:2411-2416. Another indication to the existence of multiple tumor-suppressor foci on chromosome 8p.
32. Lacombe L, Orlow I, Reuter VE, Fair WR, Dalbagni G, Zhang ZF, Cordoncardo C: Microsatellite instability and deletion analysis of chromosome 10 in human prostate cancer. Int J Cancer 1996, 69:110-113.
33. Eagle LR, Yin X, Brothman AR, Williams BJ, Atkin NB, Prochownik EV: Mutation of the MXM gene in prostate cancer. Nature Genetics 1995, 9:249-252.
34. Gray IC, Phillips SM, Lee SJ, Neoptolemos JP, Weissenbach J, Spurr NK: Loss of the chromosomal region 10q23-25 in prostate cancer. Cancer Res 1995, 55:4800-4803. Allelic loss on chromosome 10q23-25 is at the 10q23-24 boundary.
35. Cher ML, Ito T, Weidner N, Carroll PR, Jensen RH: Mapping of regions of physical deletion on chromosome 16q in prostate cancer cells by fluorescence in situ hybridization (FISH). J Urol 1995, 153:249-254
36. Latil A, Cussenot O, Fournier G, Baron JC, Lidereau R: Loss of heterozygosity at 7q31 is a frequent and early event in prostate cancer. Clin Cancer Res 1995, 1:1385-1389. This paper discusses allelic loss at 7q31 and its frequency in prostate cancer.
37. Takahashi S, Shan AL, Ritland SR, Delacey KA, Bostwick DG, Lieber MM, Thibodeau SN, Jenkins RB: Frequent loss of heterozygosity at 7q31.1 in primary prostate cancer is associated with tumor aggressiveness and progression. Cancer Res 1995, 55:4114-4119. Allelic loss at 7q31 and its possible ability to participate in the progression of prostate cancer is discussed.
38. Trybus TM, Burgess AC, Wojno KJ, Glover TW, Macoska JA: Distinct areas of allelic loss on chromosomal regions 10p and 10q in human prostate cancer. Cancer Res 1996, 56:2263-2267.
39. Gao X, Zacharek A, Salkowski A, Grignon DJ, Sakr W, Porter AT, Honn KV: Loss of heterozygosity of the BRCA1 and other loci on chromosome 17q in human prostate cancer. Cancer Res 1995, 55.1002-1005.
40. Honchel R, Hailing KC, Thibodeau SN: Genomic instability in neoplasia. Semin Cell Biol 1995, 6:45-52.
41. Terrell RB, Wille AH, Cheville JC, Nystuen AM, Cohen MB, Sheffield VC: Microsatellite instability in adenocarcinoma of the prostate. Am J Pathol 1995, 147:799-805.
42. Suzuki H, Komiya A, Aida S, Akimoto S, Shiraishi T, Yatani R, Igarashi T, Shimazaki J: Microsatellite instability and other molecular abnormalities in human prostate cancer. Jpn J Cancer Res 1995, 86:956-961.
43. Watanabe M, Imai H, Shiraishi T, Shimazaki J, Kotake T, Yatani R: Microsatellite instability in human prostate cancer. Br J Cancer 1995, 72:562-564.
44. Uchida T, Wada C, Wang C, Ishida H, Egawa S, Yokoyama E, Ohtani H, Koshiba K: Microsatellite instability in prostate cancer. Oncogene 1995, 10:1019-1022.
45. Brooks JD, Bova GS, Ewing CM, Piantadosi S, Carter BS, Robinson JC, Epstein JI, Isaacs WB: An uncertain role for p53 gene alterations in human prostate cancers. Cancer Res 1996, 56:3814-3822.
46. Kunimi K, Amano T, Uchibayashi T: Point mutation of the p53 gene is an infrequent event in untreated prostate cancer. Cancer Detect Prevent 1996, 20:218-222
47. Cohen RJ, Cooper K, Haffejee Z, Robinson E, Becker PJ: Immunohistochemical detection of oncogene proteins and neuroendocrine differentiation in different stages of prostate cancer. Pathology 1995, 27:229-232.
48. Kubota Y, Shuin T, Uemura H, Fujinami K, Miyamoto H, Torigoe S, Dobashi Y, Kitamura H, Iwasaki Y, Danenberg K, et al.: Tumor suppressor gene p53 mutations in human prostate cancer. Prostate 1995, 27:18-24.
49. Mirchandani D, Zheng J, Miller GJ, Ghosh AK, Shibata DK, Cote RJ, Roy-Burman P: Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer. Am J Pathol 1995, 147:92-101.
50. Shurbaji MS, Kalbfleisch JH, Thurmond TS: Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer. Hum Pathol 1995, 26:106-109.
51. Wertz IE, Deitch AD, Gumerlock PH, Gandouredwards R, Chi SG, White R: Correlation of genetic and immunodetection of TP53 mutations in malignant and benign prostate tissues. Hum Pathol 1996, 27:573-580.
52. Dahiya R, Deng G, Chen KMK, Chui RM, Haughney PC, Narayan P: P53 tumour-suppressor gene mutations are mainly localised on exon 7 in human primary and metastatic prostate cancer. Br J Cancer 1996 74:264-268.
53. Ittmann MM, Wieczorek R: Alterations of the retinoblastoma gene in clinically localized, stage B prostate adenocarcinomas. Hum Pathol 1996, 27:28-34.
54. Konishi N, Hiasa Y, Tsuzuki T, Matsuda H, Tao M, Nakamura M, Naito H, Kitahori Y, Shiraishi T, Yatani R, Shimazaki J, Lin JC: Detection of Rb, p16/cdkn2 and p15(lnk4b) gene alterations with immunohistochemical studies in human prostate carcinomas. Int J Oncol 1996, 8.107-112.
55. Vesalainen S, Lipponen P: Expression of retinoblastoma gene (Rb) protein in T12M0 prostatic adenocarcinoma. J Cancer Res Clin Oncol 1995, 121:429-433.
56. Eastham JA, Truong LD, Rogers E, Kattan M, Flanders KC, Scardino PT, Thompson TC: Transforming growth factor-beta-1: comparative immunohistochemical localization in human primary and metastatic prostate cancer. Lab Invest 1995, 73:628-635.
57. Kim IY, Kim JH, Zelner DJ, Ahn HJ, Sensibar JA, Lee C: Transforming growth factor-beta-1 is a mediator of androgen-regulated growth arrest in an androgen-responsive prostatic cancer cell line, LNCaP. Endocrinology 1996, 137:991-999.
58. Morton DM, Barrack ER: Modulation of transforming growth factor beta 1 effects on prostate cancer cell proliferation by growth factors and extracellular matrix. Cancer Res 1995, 55:2596-2602.
59. Polyak K: Negative regulation of cell growth by TGF-beta. Biochim Biophys Acta 1996, 1242:185-199.
60. Kim IY, Ahn HJ, Zelner DJ, Shaw JW, Lang S, Kato R, Oefelein MG, Miyazono K, Nemeth JA, Kozlowski JM, Lee C: Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues. Clin Cancer Res 1996, 2:1255-1261.
61. Williams RH, Stapleton AMF, Yang G, Truong LD, Rogers E, Timme TL, Wheeler TM, Scardmo T, Thompson TC: Reduced levels of transforming growth factor beta receptor type II in human prostate cancer: an immunohistochemical study. CIm Cancer Res 1996, 2:635-640.
62. Kim IY, Zelner DJ, Sensibar JA, Ahn HJ, Park L, Kim JH, Lee C: Modulation of sensitivity to transforming growth factor beta-1 (TGF-beta-1) and the level of type II TGF-beta receptor in LNCaP cells by dihydrotestosterone. Exp Cell Res 1996, 222:103-110.
63. Giroldi LA, Bringuier PP, Schalken JA: Defective E-cadherin function in urological cancers: clinical implications and molecular mechanisms. Invasion Metas 1994, 14:71-81.
64. Cheng L, Nagabhushan M, Pretlow TP, Amini SB, Pretlow TG: Expression of E-cadherin in primary and metastatic prostate cancer. Am J Pathol 1996, 148:1375-1380. Reduction of E-cadherin expression is demonstrated using paraffin-embedded cancer tissues.
65. Umbas R, Isaacs WB, Bringuier PP, Schaafsma HE, Karthaus HF, Oosterhof GO, Debruyne FM, Schalken JA: Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 1994, 54:3929-3933
66. Morton RA, Ewing CM, Watkins JJ, Isaacs WB: The E-cadherin cell-cell adhesion pathway in urologic malignancies. World J Urol 1995, 13:364-368,
67. Carruba G, Miceli D, D'Amico D, Farruggio R, Comito L, Montesanti A, Polito L, Castagnetta LA: Sex steroids up-regulate E-cadherin expression in hormone-responsive LNCaP human prostate cancer cells. Biochem Biophys Res Commun 1995, 212:624-631.
68. Graff JR, Herman JG, Lapidus RG, Chopra H, Xu R, Jarrard DF, Isaacs WB, Pitha PM, Davidson NE, Baylin SB: E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res 1995, 55:5195-5199.
69. Ewing CM, Ru N, Morton RA, Robinson JC, Wheelock MJ, Johnson KR, Barrett JC, Isaacs WB: Chromosome 5 suppresses tumorigenicity of PC3 prostate cancer cells: correlation with re-expression of alpha-catenin and restoration of E-cadherin function. Cancer Res 1995, 55:4813-4817.
70. Gingrich JR, Barrios RJ, Morton RA, Boyce BF, Demayo FJ, Finegold MJ, Angelopoulou R, Rosen JM, Greenberg NM: Metastatic prostate cancer In a transgenic mouse. Cancer Res 1996, 56:4096-4102. Association of E-cadherin downregulation and tumor progression in transgenic models is discussed.
71. Hsieh JT, Luo W, Song W, Wang Y, Kleinerman DI, Van NT, Lin SH: Tumor suppressive role of an androgen-regulated epithelial cell adhesion molecule (C-CAM) in prostate carcinoma cell revealed by sense and antisense approaches. Cancer Res 1995, 55:190-197.
72. Kleinerman DI, Troncoso P, Lin SH, Pisters LL, Sherwood ER, Brooks T, von Eschenbach AC, Hsieh JT: Consistent expression of an epithelial cell adhesion molecule (C-CAM) during human prostate development and loss of expression in prostate cancer: implication as a tumor suppressor. Cancer Res 1995, 55:1215-1220.
73. Kallakury BVS, Yang F, Figge J, Smith KE, Kausik SJ, Tacy NJ, Fisher HAG, Kaufman R, Figge H, Ross JS: Decreased levels of CD44 protein and mRNA in prostate carcinoma: correlation with tumor grade and ploidy. Cancer 1996, 78:1461-1469.
74. Jung K, Lein M, Weiss S, Schnorr D, Henke W, Loening S: Soluble CD44 molecules in serum of patients with prostate cancer and benign prostatic hyperplasia. Eur J Cancer 1996, 32A:627-630.
75. Zhang XH, Sakamoto H, Takenaka I: Accumulation of p53 and expression of CD44 in human prostatic cancer and benign prostatic hyperplasia: an immunohistochemical study. Br J Urol 1996, 77:441-444.
76. Lokeshwar BL, Lokeshwar VB, Block NL: Expression of CD44 in prostate cancer cells: association with cell proliferation and invasive potential. Anticancer Res 1995, 15:1191-1198,
77. Bourguignon LYW, Iida N, Welsh CF, Zhu D, Krongrad A, Pasquale D: Involvement of CD44 and its variant isoforms in membrane-cytoskeleton interaction, cell adhesion and tumor metastasis. J Neuro-Oncol 1995, 26:201-208.
78. Welsh CF, Zhu D, Bourguignon LY: Interaction of CD44 variant isoforms with hyaluronic acid and the cytoskeleton in human prostate cancer cells. J Cell Physiol 1995, 164:605-612.
79. Cress AE, Rabmovitz I, Zhu WG, Nagle RB: The alpha-6-beta-1 and alpha-6-beta-4 integrins in human prostate cancer progression. Cancer Metas Rev 1995, 14:219-228. A review article on integrins and human prostate cancer.
80. Nagle RB, Hao JS, Knox JD, Dalkin BL, Clark V, Cress AE: Expression of hemidesmosomal and extracellular matrix proteins by normal and malignant human prostate tissue. Am J Pathol 1995, 146:1498-1507.
81. Rabinovitz I, Nagle RB, Cress AE: Integrin alpha 6 expression in human prostate carcinoma cells is associated with a migratory and invasive phenotype in vitro and in vivo. Clin Exp Metas 1995, 13:481-491.
82. Fornaro M, Tallini G, Bofetiado CJM, Bosari S, Languino LR: Down-regulation of beta(1) integrin, an inhibitor of cell proliferation, in prostate carcinoma. Am J Pathol 1996, 149:765-773.
83. Kostenuik PJ, Sanchezsweatman O, Orr FW, Singh G: Bone cell matrix promotes the adhesion of human prostatic carcinoma cells via the alpha-2-beta-1 integrin. Clin Exp Metas 1996, 14:19-26.
84. Dong J-T, Lamb PW, Rinker-Schaeffer CW, Vukanovic J, Ichikawa T, Isaacs JT, Barrett JC: KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 1995, 268:884-886.
85. Adachi M, Taki T, Ieki Y, Huang CL, Higashiyama M. Miyake M: Correlation of KAI1/CD82 gene expression with good prognosis in patients with non-small cell lung cancer. Cancer Res 1996, 56:1751-1755.
86. Dong JT, Suzuki H, Pin SS, Bova GS, Schalken JA, Isaacs WB, Barrett JC, Isaacs JT: Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res 1996, 56:4387-4390. A newly identified metastasis-suppressor gene is involved in prostate cancer progression.
87. Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R: Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 1995, 55:4438-4445.
88. Shabaik AS, Krajewski S, Burgan A, Krajewski M, Reed JC: Bcl-2 protooncogene expression in normal, hyperplastic, and neoplastic prostate tissue. J Urol Pathol 1995, 3:17-27.
89. Furuya Y, Krajewski S, Epstein JI, Reed JC, Isaacs JT: Expression of bcl-2 • and the progression of human and rodent prostatic cancers. Clin Cancer Res 1996, 2:389-398. Bcl-2 is downregulated in most of metastases from prostate cancer patients.
90. Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, Song K, Kitada S, Reed JC: Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 1996, 148:1567-1576.
91. Bubendorf L, Sauter G, Moch H, Jordan P, Blochlinger A, Gasser TC, Mihatsch MJ: Prognostic significance of bcl-2 in clinically localized prostate cancer. Am J Pathol 1996, 148:1557-1565.
92. Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Srivastava S, Moul JW: Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol 1996, 156:1511-1516. The possibility of Bcl-2 as a biomarker to predict recurrence in clinically localized prostate cancer is discussed.
93. Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A: Androgen receptor status of lymph node metastases from prostate cancer. Prostate 1996, 28:129-135.
94. Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A: Distant metastases from prostate carcinoma express androgen receptor protein. Cancer Res 1995, 55:3068-3072.
95. Pertschuk LP, Schaeffer H, Feldman JG, Macchia RJ, Kim YD, Eisenberg K, Braithwaite LV, Axiotis CA, Prins G, Greene GL: Immune-staining for prostate cancer androgen receptor in paraffin identifies a subset of men with a poor prognosis. Lab Invest 1995, 73:302-305.
96. Vanderkwast TH, Tetu B, Fradet Y, Dupont A, Gomez J, Cusan L, Diamond P, Labne F: Androgen receptor modulation in benign human prostatic tissue and prostatic adenocarcinoma during neoadjuvant endocrine combination therapy. Prostate 1996, 28:227-231.
97. Maclean HE, Warne GL, Zajac JD: Deffects of androgen receptor function: from sex reversal to motor neurone disease. Mol Cell Endocrinol 1995, 112:133-141.
98. Suzuki H, Akakura K, Komiya A, Aida S, Akimoto S, Shimazaki J: Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome. Prostate 1996, 29:153-158.
99. Tilley WD, Buchanan G, Hickey TE, Bentel JM: Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 1996, 2:277-285. Mutation in androgen receptor gene is common in advanced prostate cancer.